{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:38:16Z","timestamp":1791599896308,"version":"4.3.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Minerva Neurosciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. Roluperidone administered as monotherapy to patients suffering from mild to moderate negative symptoms and withdrawal from antipsychotic drugs, improved negative symptoms in 2 clinical trials. The patients who were symptomatically stable for 3 or 6 months before antipsychotic drug withdrawal showed a very low rate of psychotic symptoms worsening over 6 or 9-month trial duration.<\/jats:p>\n               <jats:p>Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.<\/jats:p>","DOI":"10.1093\/ijnp\/pyaf032","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:12:06Z","timestamp":1747739526000},"source":"Crossref","is-referenced-by-count":5,"title":["Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-1719","authenticated-orcid":false,"given":"Michael","family":"Davidson","sequence":"first","affiliation":[{"name":"Minerva Neurosciences , 1500 District Avenue Burlington, MA 01803 ,","place":["USA"]},{"name":"Clinical and Basic Sciences Department Nicosia University Medical School , Nicholas St 93, Egkomi Lefkosias 2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Noel","sequence":"additional","affiliation":[{"name":"PPRS SAS , PPRS, 4e Av. du G\u00e9n\u00e9ral de Gaulle, 68000 Colmar ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Schmitt","sequence":"additional","affiliation":[{"name":"PPRS SAS , PPRS, 4e Av. du G\u00e9n\u00e9ral de Gaulle, 68000 Colmar ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Luthringer","sequence":"additional","affiliation":[{"name":"Minerva Neurosciences , 1500 District Avenue Burlington, MA 01803 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"2025100309014850700_CIT0001","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/schbul\/sby095","article-title":"How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials","volume":"45","author":"Samara","year":"2019","journal-title":"Schizophr Bull."},{"key":"2025100309014850700_CIT0002","doi-asserted-by":"publisher","first-page":"73","DOI":"10.31887\/DCNS.2020.22.1\/mdavidson","article-title":"Do DSM classifications help or hinder drug development","volume":"22","author":"Davidson","year":"2020","journal-title":"Dialogues Clin Neurosci."},{"key":"2025100309014850700_CIT0003","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41588-019-0397-8","article-title":"Genome-wide association study identifies 30 loci associated with bipolar disorder","volume":"51","author":"Stahl","year":"2019","journal-title":"Nat Genet."},{"key":"2025100309014850700_CIT0004","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41380-017-0010-4","article-title":"Psychiatric genetics and the structure of psychopathology","volume":"24","author":"Smoller","year":"2019","journal-title":"Mol Psychiatry."},{"key":"2025100309014850700_CIT0005","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: a review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am J Psychiatry."},{"key":"2025100309014850700_CIT0006","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1176\/appi.ajp.162.3.433","article-title":"Toward a philosophical structure for psychiatry","volume":"162","author":"Kendler","year":"2005","journal-title":"Am J Psychiatry."},{"key":"2025100309014850700_CIT0007","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/schbul\/sbad145","article-title":"Targeted treatment of schizophrenia symptoms as they manifest, or continuous treatment to reduce the risk of psychosis recurrence","volume":"50","author":"Davidson","year":"2024","journal-title":"Schizophr Bull."},{"key":"2025100309014850700_CIT0008","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am J Psychiatry."},{"key":"2025100309014850700_CIT0009","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.11.013","article-title":"Quantitative neurosymptomatics: linking quantitative biology to neuropsychiatry","volume":"97","author":"Kas","year":"2019","journal-title":"Neurosci Biobehav Rev."},{"key":"2025100309014850700_CIT0010","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/schbul\/sbx066","article-title":"A transdiagnostic review of negative symptom phenomenology and etiology","volume":"43","author":"Strauss","year":"2017","journal-title":"Schizophr Bull."},{"key":"2025100309014850700_CIT0011","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41583-018-0029-9","article-title":"Neuroscience of apathy and anhedonia: a transdiagnostic approach","volume":"19","author":"Husain","year":"2018","journal-title":"Nat Rev Neurosci."},{"key":"2025100309014850700_CIT0012","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/ijnp\/pyad011","article-title":"New developments in the treatment of schizophrenia: an expert roundtable","volume":"26","author":"Kantrowitz","year":"2023","journal-title":"Int J Neuropsychopharmacol."},{"key":"2025100309014850700_CIT0013","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.schres.2023.07.010","article-title":"Negative symptoms in schizophrenia: newly emerging measurements, pathways, and treatments","volume":"258","author":"Marder","year":"2023","journal-title":"Schizophr Res."},{"key":"2025100309014850700_CIT0014","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2023.03.028","article-title":"Long-term effects of Roluperidone on negative symptoms of schizophrenia","volume":"255","author":"Rabinowitz","year":"2023","journal-title":"Schizophr Res."},{"key":"2025100309014850700_CIT0015","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41586-021-04175-x","article-title":"Structures of the \u03c32 receptor enable docking for bioactive ligand discovery","volume":"600","author":"Alon","year":"2021","journal-title":"Nature."},{"key":"2025100309014850700_CIT0016","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/med.22086","article-title":"Current emerging therapeutic targets and clinical investigational agents for schizophrenia: challenges and opportunities","volume":"45","author":"Ye","year":"2025","journal-title":"Med Res Rev."},{"key":"2025100309014850700_CIT0017","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0014-2999(95)00208-3","article-title":"Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism","volume":"280","author":"Matsumoto","year":"1995","journal-title":"Eur J Pharmacol."},{"key":"2025100309014850700_CIT0018","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0091-3057(98)00146-4","article-title":"Possible involvement of a sigma receptor subtype in the neck dystonia in rats","volume":"62","author":"Nakazawa","year":"1999","journal-title":"Pharmacol Biochem Behav."},{"key":"2025100309014850700_CIT0019","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s0091-3057(84)80102-1","article-title":"Serotonergic involvement in phencyclidine-induced behaviors","volume":"21","author":"Nabeshima","year":"1984","journal-title":"Pharmacol Biochem Behav."},{"key":"2025100309014850700_CIT0020","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0014-2999(81)90086-8","article-title":"Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats","volume":"73","author":"Castellani","year":"1981","journal-title":"Eur J Pharmacol."},{"key":"2025100309014850700_CIT0021","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1248\/yakushi1947.107.8_548","article-title":"[Recent topics of phencyclidine, the drug induces psychosis]","volume":"107","author":"Nabeshima","year":"1987","journal-title":"Yakugaku Zasshi."},{"key":"2025100309014850700_CIT0022","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ajmg.b.31128","article-title":"Effects of the BDNF val66met polymorphism on prefrontal brain function in a population at high genetic risk of schizophrenia","volume":"153B","author":"Whalley","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2025100309014850700_CIT0023","doi-asserted-by":"publisher","first-page":"104879","DOI":"10.1016\/j.psyneuen.2020.104879","article-title":"BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: a prospective 12-week longitudinal study","volume":"122","author":"Wu","year":"2020","journal-title":"Psychoneuroendocrinology."},{"key":"2025100309014850700_CIT0024","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","article-title":"Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia","volume":"174","author":"Davidson","year":"2017","journal-title":"Am J Psychiatry."},{"key":"2025100309014850700_CIT0025","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr Bull."},{"key":"2025100309014850700_CIT0026","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/schbul\/sbz141","article-title":"Network analysis indicates that avolition is the most central domain for the successful treatment of negative symptoms: evidence from the roluperidone randomized clinical trial","volume":"46","author":"Strauss","year":"2020","journal-title":"Schizophr Bull."},{"key":"2025100309014850700_CIT0027","doi-asserted-by":"crossref","first-page":"11956","DOI":"10.4088\/JCP.17m11753","article-title":"Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial","volume":"79","author":"Keefe","year":"2018","journal-title":"J Clin Psychiatry."},{"key":"2025100309014850700_CIT0028","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/schbul\/sbt034","article-title":"Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery","volume":"39","author":"Harrow","year":"2013","journal-title":"Schizophr Bull."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf032\/63244444\/pyaf032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/6\/pyaf032\/63244444\/pyaf032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/6\/pyaf032\/63244444\/pyaf032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:01:53Z","timestamp":1759496513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf032\/8138412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf032","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,20]]},"article-number":"pyaf032"}}